| EN
We employ a market oriented approach to R&D, addressing significant unmet medical needs, and focus our R&D efforts on innovative and high entry-barrier generic pharmaceuticals in oncology, central nervous system and autoimmune disease therapeutic areas. We are one of the few pharmaceutical companies headquartered in China that have developed and launched 3 category I innovative pharmaceuticals and 1 imported innovative pharmaceutical. Over 10 products are recommended in more than 50 clinical practice guidelines and pathways issued by government authorities or prestigious professional associations, and over 40 products are included in the NRDL.

Oncology

  • Endostar®
  • Jepaso®
  • JIEBAILI®
  • Sinofuan®
  • Enlength®
  • Enlighten

Central Nervous System

  • Sanbexin®
  • BICUN®
  • Ancozy®

Autoimmune

  • Iremod®
  • Orencia®
  • AIJIEWEI®
  • Antine®
  • RUIFUSHU

Cardiovascular

  • OLMETEC PLUS®
  • Softan®
  • XINTA®
  • XINSHIPING

Anti-infection

  • Newanti®
  • ZAILIKE®
  • YEQING®
  • ANQI®
  • ZAILIN®
  • ZAIKE®
  • LIHONG

Other Fields

  • BIQI®
  • Lowvo®
  • 结敏®
  • KECHUANNING
  • FANENG®
  • OUDIJIA®
  • DING'AN®

Search

[Disclaimer: Please use prescription drugs under the guidance of practicing doctors. Check only the instructions inside the packaging for valid product details.]